OHP-006 Continuous venovenous haemofiltration in critically ill patients: Pratice assessment and cost impact

• Published in: European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A174-A174
• Main Authors: Jean-Bart, E, Bel, F, Morey, F, Bruyère, R, Sedillot, N
• Format: Article
• Language: English
• Subjects: Consumption; Cost control; Pharmacists
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2016-000875.394

BackgroundFor patients hospitalised in our intensive care unit (ICU), continuous venovenous haemofiltration (CVVH) with citrate has been implemented since 2013. This study was conducted to assess the change in practices and restitution fluids (RF), analysing the impact on consumption and costs. Reflection on this was conducted between physicians, nurses and pharmacists.PurposeThe aim of the study was to assess the cost implications of citrate anticoagulation.Material and methodsWe performed a retrospective study in the ICU in patients requiring CVVH in 2014. Data collected were: patient characteristics (age, sex ratio, BMI, IGS2) and CVVH data (indications, effective duration, filters, RF, calcium and phosphorus consumption). Prescription data allowed estimation of the total cost with RF, filters and ion consumption. Costs of other RF with integrated ions were used to simulate the cost impact. Results were expressed for 24 h of effective CVVH. The citrate and non-citrate groups were compared with the Student’s test (significant if p < 0.05).ResultsWe included 64 patients. They had a mean age of 68.1 ± 16.6 years, a mean SAPS II of 58.2 ± 20.5, a mean stay in the ICU of 9.0 ± 9.6 days and a mortality rate of 28.1%. Volume overload was an indication for CVVH in 46.8% of patients, hyperkaliaema in 31.2% and acidosis in 14.2%. Duration was